{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:19:54Z","timestamp":1740143994994,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T00:00:00Z","timestamp":1461888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited (GB)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40258-016-0244-3","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T05:58:08Z","timestamp":1461909488000},"page":"545-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-5850","authenticated-orcid":false,"given":"Stephen","family":"Montgomery","sequence":"first","affiliation":[]},{"given":"Jeanette","family":"Kusel","sequence":"additional","affiliation":[]},{"given":"Felicity","family":"Allen","sequence":"additional","affiliation":[]},{"given":"Nicholas","family":"Adlard","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,4,29]]},"reference":[{"issue":"1","key":"244_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health."},{"issue":"1","key":"244_CR2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40258-013-0064-7","volume":"12","author":"K Vooren van de","year":"2014","unstructured":"van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014;12(1):33\u201340.","journal-title":"Appl Health Econ Health Policy."},{"issue":"6","key":"244_CR3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00019053-200119060-00001","volume":"19","author":"P Trueman","year":"2001","unstructured":"Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics. 2001;19(6):609\u201321.","journal-title":"Pharmacoeconomics."},{"key":"244_CR4","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. http:\/\/www.nice.org.uk\/article\/PMG9\/chapter\/Foreword . Accessed 30 Jan 2015."},{"key":"244_CR5","unstructured":"National Institute for Health and Care Excellence. Assessing cost impact: methods guide. 2011. http:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/Into-practice\/Costing_Manual_update_050811.pdf . Accessed 30 Jan 2015."},{"key":"244_CR6","unstructured":"National Institute for Health and Care Excellence. Resource impact assessment methods guide consultation. 2015. https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/Into-practice\/costing\/ria-method-guide-revision-V12-consultation.pdf . Accessed 11 Sep 2015."},{"key":"244_CR7","unstructured":"NHS England. NHS five year forward view. 2014. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2014\/10\/5yfv-web.pdf . Accessed 14 Apr 2016."},{"issue":"4","key":"244_CR8","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1172\/JCI58649","volume":"122","author":"A Nylander","year":"2012","unstructured":"Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122(4):1180\u20138.","journal-title":"J Clin Invest."},{"issue":"1","key":"244_CR9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/jnnp-2013-305450","volume":"85","author":"IS Mackenzie","year":"2014","unstructured":"Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O\u2019Riordan J. Incidence and prevalence of multiple sclerosis in the UK 1990\u20132010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry. 2014;85(1):76\u201384.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"9313","key":"244_CR10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","volume":"359","author":"A Compston","year":"2002","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221\u201331.","journal-title":"Lancet."},{"key":"244_CR11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/B978-0-444-52001-2.00024-8","volume":"122","author":"J Derwenskus","year":"2014","unstructured":"Derwenskus J, Lublin FD. Future treatment approaches to multiple sclerosis. Handb Clin Neurol. 2014;122:563\u201377.","journal-title":"Handb Clin Neurol."},{"key":"244_CR12","unstructured":"electronic Medicines Compendium (eMC). TYSABRI 300\u00a0mg concentrate for solution for infusion. 25 Nov 2013. http:\/\/www.medicines.org.uk\/emc\/medicine\/18447 . Accessed 30 Jan 2015."},{"key":"244_CR13","unstructured":"electronic Medicines Compendium (eMC). Gilenya 0.5\u00a0mg hard capsules. 08 Sep 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/24443\/SPC\/ . Accessed 30 Jan 2015."},{"key":"244_CR14","unstructured":"electronic Medicines Compendium (eMC). Tecfidera 240\u00a0mg gastro-resistant hard capsules. 27\u00a0Aug 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/28593 . Accessed 30 Jan 2015."},{"key":"244_CR15","unstructured":"electronic Medicines Compendium (eMC). AUBAGIO 14\u00a0mg film-coated tablets. 22\u00a0Sep 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/28533 . Accessed 30 Jan 2015."},{"key":"244_CR16","unstructured":"electronic Medicines Compendium (eMC). LEMTRADA 12\u00a0mg concentrate for solution for infusion. 15\u00a0Dec 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/28917 . Accessed 30 Jan 2015."},{"key":"244_CR17","unstructured":"National Institute for Health and Care Excellence. Natalizumab (Tysabri\u00ae) for the treatment of adults with highly active relapsing remitting multiple sclerosis (TA127). London: NICE; 2007. https:\/\/www.nice.org.uk\/guidance\/ta127 . Accessed 14 Apr 2016."},{"key":"244_CR18","unstructured":"National Institute for Health and Care Excellence. Fingolimod for the treatment of highly active relapsing\u2013remitting multiple sclerosis (TA254). London: NICE; 2012. https:\/\/www.nice.org.uk\/guidance\/ta254 . Accessed 14 Apr 2016."},{"key":"244_CR19","unstructured":"National Institute for Health and Care Excellence. Teriflunomide for treating relapsing\u2013remitting multiple sclerosis (TA303). London: NICE; 2014. https:\/\/www.nice.org.uk\/guidance\/ta303 . Accessed 14 Apr 2016."},{"key":"244_CR20","unstructured":"National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing\u2013remitting multiple sclerosis (TA320). London: NICE; 2014. https:\/\/www.nice.org.uk\/guidance\/ta320 . Accessed 14 Apr 2016."},{"key":"244_CR21","unstructured":"National Institute for Health and Care Excellence. Alemtuzumab for treating relapsing\u2013remitting multiple sclerosis (TA312). London: NICE; 2014. https:\/\/www.nice.org.uk\/guidance\/ta312 . Accessed 14 Apr 2016."},{"key":"244_CR22","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139, W64."},{"key":"244_CR23","unstructured":"Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Updated March 2011. http:\/\/handbook.cochrane.org\/ . Accessed 2 Mar 2015."},{"issue":"5","key":"244_CR24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00005650-200205000-00004","volume":"40","author":"F Sassi","year":"2002","unstructured":"Sassi F, Archard L, McDaid D. Searching literature databases for health care economic evaluations: how systematic can we afford to be? Med Care. 2002;40(5):387\u201394.","journal-title":"Med Care."},{"key":"244_CR25","unstructured":"Biogen Idec Ltd. Natalizumab (Tysabri\u00ae) for the treatment of adults with highly active relapsing remitting multiple sclerosis. Manufacturer submission of evidence to NICE. TA127. London: National Institute for Health and Clinical Excellence; 2007."},{"key":"244_CR26","unstructured":"Biogen Idec Ltd. Dimethyl fumarate for the treatment of adult patients with relapsing remitting multiple sclerosis. Manufacturer submission of evidence. TA320. London: National Institute for Health and Care Excellence; 2013."},{"key":"244_CR27","unstructured":"Genzyme. Alemtuzumab for the treatment of relapsing remitting multiple sclerosis in adults. Manufacturer submission of evidence. TA312. London: National Institute for Health and Care Excellence; 2013."},{"key":"244_CR28","unstructured":"Genzyme. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis in adults. Manufacturer submission of evidence. TA303. London: National Institute for Health and Care Excellence; 2013."},{"key":"244_CR29","unstructured":"Novartis Pharmaceuticals UK Ltd. Fingolimod for the treatment of relapsing-remitting multiple sclerosis in adults. Manufacturer submission of evidence. TA254. London: National Institute for Health and Clinical Excellence; 2011."},{"issue":"1","key":"244_CR30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/09540261003589216","volume":"22","author":"E Koutsouraki","year":"2010","unstructured":"Koutsouraki E, Costa V, Baloyannis S. Epidemiology of multiple sclerosis in Europe: a review. Int Rev Psychiatry. 2010;22(1):2\u201313.","journal-title":"Int Rev Psychiatry."},{"issue":"5","key":"244_CR31","doi-asserted-by":"crossref","first-page":"A387","DOI":"10.1016\/j.autrev.2009.11.010","volume":"9","author":"R Milo","year":"2010","unstructured":"Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9(5):A387\u201394.","journal-title":"Autoimmun Rev."},{"key":"244_CR32","unstructured":"Multiple Sclerosis Trust. Multiple sclerosis information for health and social care professionals. 4th ed. Letchworth Garden City: MS Trust; 2011. http:\/\/www.mstrust.org.uk\/health-professionals\/practice-resources\/ms-information-health-and-social-care-professionals . Accessed 14 Apr 2016."},{"issue":"Suppl 2","key":"244_CR33","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1007\/s10198-006-0380-z","volume":"7","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, Nixon R. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ. 2006;7(Suppl 2):S96\u2013104.","journal-title":"Eur J Health Econ."},{"key":"244_CR34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2377-10-88","volume":"10","author":"JP Zajicek","year":"2010","unstructured":"Zajicek JP, Ingram WM, Vickery J, Creanor S, Wright DE, Hobart JC. Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort. BMC Neurol. 2010;10:88.","journal-title":"BMC Neurol."},{"issue":"9","key":"244_CR35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, AFFIRM Investigators, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910.","journal-title":"N Engl J Med."},{"key":"244_CR36","unstructured":"Department of Health. Cost effective provision of disease modifying therapies for people with multiple sclerosis. London: Department of Health; 2002. http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@en\/documents\/digitalasset\/dh_4012214.pdf . Accessed 14 Apr 2016."},{"issue":"2","key":"244_CR37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11845-011-0773-6","volume":"181","author":"A Dee","year":"2012","unstructured":"Dee A, Hutchinson M, De La Harpe D. A budget impact analysis of natalizumab use in Ireland. Ir J Med Sci. 2012;181(2):199\u2013204.","journal-title":"Ir J Med Sci."},{"key":"244_CR38","unstructured":"Health and Social Care Information Centre. Use of NICE appraised medicines in the NHS in England\u2014experimental statistics. 2009. http:\/\/www.hscic.gov.uk\/catalogue\/PUB01400\/use-nice-app-med-nhs-exp-stat-eng-exp.pdf . Accessed 14 Sep 2015."},{"key":"244_CR39","unstructured":"ICJME. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. 2014. http:\/\/www.icmje.org\/recommendations\/browse\/manuscript-preparation\/preparing-for-submission.html#g . Accessed 11 Nov 2015."},{"key":"244_CR40","unstructured":"Health and Social Care Information Centre. Use of NICE appraised medicines in the NHS in England\u20142012, experimental statistics. 2014. http:\/\/www.hscic.gov.uk\/catalogue\/PUB13413\/use-nice-app-med-nhs-exp-stat-eng-12-rep.pdf . Accessed 14 Sep 2015."},{"key":"244_CR41","unstructured":"Health and Social Care Information Centre. NICE technology appraisals in the NHS in England (innovation scorecard): to September 2014, experimental statistics. Estimates of predicted use compared to observed use. 2015. http:\/\/www.hscic.gov.uk\/catalogue\/PUB17559\/nice-tech-apps-eng-may15-exp-inno-scor-est.pdf . Accessed 14 Sep 2015."},{"key":"244_CR42","unstructured":"NHS England Clinical Reference Group for Neurosciences. Clinical commissioning policy: disease modifying therapies for patients with multiple sclerosis (MS). Reference: NHS ENGLAND\/D04\/P\/b. Updated May 2014. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2013\/10\/d04-p-b.pdf . Accessed 14 Apr 2016."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-016-0244-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-016-0244-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-016-0244-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-016-0244-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:28:43Z","timestamp":1559489323000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-016-0244-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,29]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["244"],"URL":"https:\/\/doi.org\/10.1007\/s40258-016-0244-3","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"type":"print","value":"1175-5652"},{"type":"electronic","value":"1179-1896"}],"subject":[],"published":{"date-parts":[[2016,4,29]]}}}